New Phase 3 trial: A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055) — Merck Sharp & Dohme LLC
Why now
Thesis: Advances Merck oncology pipeline with ADC-IO combination in bladder cancer.
Catalyst to watch: Efficacy data versus current bladder cancer standards.
Main risk: ADC safety or combination toxicity may limit use.
Why it matters
A bladder cancer combination trial advances Merck's oncology pipeline with an antibody-drug conjugate.
Details
Sponsor: Merck Sharp & Dohme LLC; Status: Not Yet Recruiting; Conditions: Bladder Cancer; Interventions: Sac-TMT, Pembrolizumab and Berahyaluronidase alfa, Cisplatin; Enrollment: 400 (estimated); First posted: 2026-09-21; NCT: NCT07829783
Related assets & topics
HealthcareSources
- clinicaltrials · 2026-09-21 12:00 UTC